ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
DCGI approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung diseas
May 21, 2020Approval is based on the SENSCIS study which showed Nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD). -
Boehringer Ingelheim gets EC approval for nintedanib to treat SSc-ILD
April 26, 2020Boehringer Ingelheim has secured approval from the European Commission (EC) for its nintedanib to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adult patients. -
FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)
September 09, 2019The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated...
Pharma Sources Insight January 2025
